Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000935
Chunk: 4

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 4
---
 (as
defined in the Purchase Agreement) on the applicable Additional VWAP Purchase Date.

| 2 |

If
the Company makes certain issuances of Company securities within a specified period of time after a Purchase Date and such securities
are issued at prices (the “New Issuance Price”) less than the prices to be paid by the Purchaser in such Fixed Purchase, VWAP
Purchase or Additional VWAP Purchase, the purchase price for such applicable Fixed Purchase, VWAP Purchase and Additional VWAP Purchase
would be reduced to the New Issuance Price, subject to the terms and conditions set forth in the Purchase Agreement.

Under
the Purchase Agreement, in no event may the aggregate amount of Purchase Shares submitted in any single or combination of VWAP Purchase
notices and/or Additional VWAP Purchase notices on a particular date require a payment from the Purchaser to the Company that exceeds
$2,500,000, unless such limitation is waived by the Purchaser.

In addition, the
Purchaser is not obligated to buy any Ordinary Shares (including Ordinary Shares represented by Depositary Shares) pursuant to the Purchase
Agreement if such Ordinary Shares (including Ordinary Shares represented by Depositary Shares), when aggregated with all other Ordinary
Shares (including Ordinary Shares represented by Depositary Shares) then beneficially owned by the Purchaser and its affiliates (as calculated
pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 promulgated thereunder) following the applicable
purchase by the Purchaser, would result in the Purchaser beneficially owning Ordinary Shares (including Ordinary Shares represented by
Depositary Shares) in excess of 4.99% of the then-outstanding Ordinary Shares (including Ordinary Shares represented by Depositary Shares)
following such purchase or acquisition by the Purchaser (the “Beneficial Ownership Limitation”), provided, however, the Purchaser
may increase the Beneficial Ownership Limitation up to 9.99% at its sole discretion upon sixty-one days’ prior written notice to
the Company. For the avoidance of doubt, the Beneficial Ownership Limitation in no event will exceed 9.99% of the number of Ordinary Shares
(including Ordinary Shares represented by Depositary Shares) outstanding immediately after giving effect to the issuance of shares of
Ordinary Shares (including Ordinary Shares represented by Depositary Shares) pursuant to the Purchase Agreement.

The
net proceeds under the Purchase Agreement to the Company will depend on